Migratory Pulmonary Infiltrates in a B-Cell-Depleted COVID-19 Patient

Infect Drug Resist. 2023 Nov 13:16:7205-7208. doi: 10.2147/IDR.S439795. eCollection 2023.

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still rampant around the world. Immunocompromised patients are prone to have long-term infection with coronavirus disease 2019 (COVID-19). However, it is difficult to decide on an appropriate treatment for persistent SARS-CoV-2 infection.

Case presentation: We present a case of prolonged SARS-CoV-2 infection in a patient who had undergone B-cell depletion therapy. Chest computed tomography (CT) revealed notable migratory pulmonary infiltrates, and bronchoalveolar lavage fluid was positive for SARS-CoV-2 (day-120). The patient responded well to the combination treatment of antiviral medication, convalescent plasma, and corticosteroid.

Conclusion: When chest CT shows migratory pulmonary infiltrates in patients with recent COVID-19, it is necessary to be alert to the possibility of persistent SARS-CoV-2 infection, especially in B-cell-depleted immunocompromised patients. Once the diagnosis is confirmed, repeated antiviral therapy and intravenous convalescent plasma should be considered.

Keywords: B-cell depletion; SARS-CoV-2; antiviral therapy; convalescent plasma; migratory pulmonary infiltrates.

Publication types

  • Case Reports

Grants and funding

National High Level Hospital Clinical Research Funding (2022‑PUMCH‑A‑010).